BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Atossa Genetics, Inc. Announces Launch of ArgusCYTE Breast Health Test(SM) for Detection of Circulating Tumor Cells


12/6/2011 8:43:02 AM

SEATTLE, WA--(Marketwire - December 06, 2011) -

Atossa Genetics, Inc., a health care company developing and commercializing a comprehensive set of innovative, proprietary breast health evaluation products and services, today announced that it has begun setting up Field Experience Sites in select markets for its new ArgusCYTE Breast Health Test(SM) for detection of circulating breast tumor cells (CTCs) in women.

"Finding circulating breast tumor cells before metastatic disease is clinically apparent affords early treatment options that can help improve long-term survival," stated Steven C. Quay, M.D., Ph.D., FCAP. "The ArgusCYTE Breast Health Test(SM) is the only CLIA-certified circulating breast tumor cell test available today that identifies mRNA expression levels for estrogen receptors (ER) progesterone receptors (PR), and HER-2 antigen in a single blood draw to help guide treatment selection by determining which of the most commonly used therapies may be effective for the individual patient. The ArgusCYTE Breast Health Test(SM) can identify circulating tumor cells at the level of less than 5 cells/5 mL blood sample and can be used immediately after a woman begins breast cancer therapy or at the time of diagnosis or biopsy so that she and her healthcare provider can make better-informed decisions about effective treatment options. Analytical validation studies performed by Atossa Genetics demonstrated a sensitivity of 94% and specificity of 98% at the 5 cancer cell/5 mL blood sample level (n=106)."

About the ArgusCYTE Breast Health Test(SM)

The ArgusCYTE Breast Health Test(SM) is highly sensitive, providing early warning about the presence of circulating breast cancer tumor cells in a simple 'liquid biopsy' blood specimen. The ArgusCYTE Breast Health Test(SM) is the only CTC test that identifies mRNA expression levels for estrogen receptors (ER), progesterone receptors (PR), and HR-2 antigen to help guide treatment selection. Atossa expects to roll out the product nationally in 2012. For additional information on the ArgusCYTE Breast Health Test(SM), please visit http://nrlbh.com/testing-services/recurrence-monitoring.php or call 800-351-3902.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is a privately held health care company that provides a comprehensive set of innovative breast health evaluation products and services that provide accurate and actionable results for personalized cancer prevention and breast health. Atossa has established the National Reference Laboratory for Breast Health, a specially equipped, CLIA-registered laboratory located in Seattle, Washington, that provides comprehensive test results to guide personalized breast cancer prevention and treatment solutions. Patients, health care providers, investors and others seeking information on Atossa and its products and services should visit www.atossagenetics.com.


Contacts:

Steven C. Quay, M.D., Ph.D., FCAP (Corporate)
Chairman, President and CEO of Atossa Genetics and Director of the National Reference Laboratory for Breast Health
206-325-6086
Email Contact

Matthew D. Haines (Investors and Media)
Managing Director
MBS Value Partners
212-710-9686
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES